We herein reported the first study regarding the detailed molecular mechanism underlying the pro-fibrotic effect of ET-1 on normal dermal fibroblasts and the anti-fibrotic effect of bosentan on SSc dermal fibroblasts, in which transcription factor Fli1, a potential predisposing factor in SSc, is an important target. This evidence concerns the gene FLI1 and systemic sclerosis.